RECURRENT GLIOBLASTOMA

This early-stage trial is testing a new drug called RMC-5552 in adults whose aggressive brain cancer (glioblastoma) has returned after standard treatment. The main goals are to find the safest and most effective dose and to see if the drug can help shrink tumors. The study will e…

This is a first-in-human study testing a new cell therapy called CARv3-TEAM-E for glioblastoma, an aggressive brain cancer. Researchers will collect a patient's own immune cells, genetically modify them to target cancer, and reinfuse them to see if they can safely fight the tumor…

This early study is testing a new, non-invasive treatment for glioblastoma, a fast-growing brain cancer that has returned or worsened. The treatment combines a special drug with focused ultrasound waves, guided by an MRI machine, to try to kill cancer cells without surgery. The m…

This early-stage study is testing a new personalized treatment for adults with a specific type of recurrent brain cancer called glioblastoma. Doctors take a patient's own immune cells, genetically modify them in a lab to better target the cancer, and then infuse them back into th…

This study is testing a combination of two drugs, atezolizumab and cabozantinib, for adults with glioblastoma that has returned after initial treatment. The goal is to see if this combination is safe and can help control the cancer by boosting the immune system and blocking tumor…

This study is testing a combination of three drugs—pembrolizumab, olaparib, and temozolomide—to see if they can help control recurrent glioblastoma, an aggressive brain tumor that has returned after initial treatment. The trial will enroll about 78 adults whose cancer has come ba…

This study aims to find a safe and effective schedule for delivering a second round of radiation to treat glioblastoma brain tumors that have returned after initial treatment. It will enroll 28 adults whose cancer has come back, testing radiation given four times a week for one, …

This early-stage trial is testing a new treatment for aggressive brain cancers that have returned. Doctors are using stem cells to carry a specially engineered cold virus directly to the tumor. The goal is to see if the virus can safely infect and kill the cancer cells while spar…

This is a first-in-human study testing a new type of cell therapy for adults with recurrent or progressive glioblastoma or other high-grade brain tumors. The therapy uses modified natural killer (NK) immune cells designed to recognize two specific markers on the patient's tumor. …

This early-stage study is testing the safety of a new type of treatment called CAR-T cell therapy for adults with a specific type of recurrent brain cancer (glioblastoma). Doctors will give patients modified versions of their own immune cells, either after chemotherapy or before …

This study aims to find out if the cancer drug trastuzumab deruxtecan (T-DXd) can get into brain tumors when given through an IV. Researchers will measure how much of the drug reaches the tumor during surgery in 30 adults with certain HER2-positive brain cancers or recurrent glio…

This early-stage study is testing the safety and best dose of an experimental drug called CUE-102 in adults whose glioblastoma brain cancer has returned for the first time. CUE-102 is designed to activate the body's immune system to fight the tumor. The study will enroll about 18…

This study is testing a new way to treat glioblastoma, a very aggressive brain cancer that has come back after initial treatment. Doctors will place tiny radioactive seeds directly into the tumor to deliver radiation from the inside. The main goals are to see if this procedure is…

This is a first-in-human, early-stage trial testing the safety and initial effectiveness of a new type of CAR-T cell therapy called EPC-003 for adults with recurrent or treatment-resistant glioblastoma, a serious brain cancer. The therapy involves collecting and genetically modif…

This study is testing if an immunotherapy drug called atezolizumab can help control recurrent glioblastoma, a very aggressive brain cancer. Researchers are focusing on patients whose tumors have a specific genetic feature called 'low tumor mutational burden.' The goal is to see i…

This study is testing whether a new combination of two immunotherapy drugs (relatlimab and nivolumab) works better and is safer than the standard chemotherapy (lomustine) for glioblastoma that has returned after initial treatment. The trial will involve about 184 adults whose bra…

This early study is testing a new device called TheraSphere GBM that delivers targeted radiation directly to recurrent glioblastoma brain tumors. The research aims to see if this approach is safe and technically possible for patients whose cancer has returned after standard treat…

This early study is testing whether the drug troriluzole can help control recurrent glioblastoma, an aggressive brain cancer. About 27 adults whose cancer has returned will receive the drug either before and after standard tumor-removal surgery, or only after surgery, to see if i…

This study is testing the safety and effectiveness of a new drug called pumitamig, both alone and in combination with other cancer drugs, for adults whose aggressive brain cancer (glioblastoma) has returned after initial treatment. The goal is to see if these treatments can shrin…

This study is testing the safety and feasibility of a three-part treatment for adults whose aggressive brain cancer (glioblastoma) has returned. The treatment combines a wearable device that uses electric fields to disrupt cancer cells, a precise laser surgery to destroy the tumo…

This study aims to understand the biology of glioblastoma, a serious brain cancer, by analyzing MRI scans. Researchers will study 50 adults with this cancer who are scheduled for surgery. The goal is to find patterns in the scans that might predict which patients could benefit fr…

This study aims to learn more about glioblastoma, an aggressive brain cancer, by using two types of specialized PET scans and a powerful MRI machine. Researchers will scan up to 15 adults with new or returning glioblastoma who are already scheduled for surgery. The goal is to see…